

- de dose controlada e câmara expansora: dose segura e eficaz de salbutamol. *Rev Port Med Geral Fam.* 2013;29:114–9.
68. Sousa M. Treatment of cough associated with upper respiratory tract infections in children: what is the best evidence?; 2010.
 69. Silva SF, Costa N, Lança IB, Seves G, Cavaco A, Gaspar M. Tuberculose Infantil: a importância do rastreio. *Rev Port Med Geral Fam.* 2013;29:180–4.
 70. Oliveira G, Neto T, Dias C, Oliveira C, Aguiar A, Rodrigues C, et al. Uso e Abuso dos Nebulizadores no Domicílio. *Acta Pediátr Port.* 2005;36:290–6.
 71. Pacheco da Cunha AI. Vacinação Antipneumocócica em Idosos: Uma Vacina Esquecida. *Escola de Ciências da Saúde da Universidade do Minho*; 2010.
 72. Correia S. Vacinação anti-pneumocócica no idoso. *Rev Port Med Geral Fam.* 2013;29:386–93.
 73. Silva LC [Dissertações de Mestrado] Validação do questionário clínico para a doença pulmonar obstrutiva crónica (CCQ) para a língua portuguesa. Repositório Comum. ESEP; 2012.
 74. Linhares DV, da Fonseca JA, Borrego LM, Matos A, Pereira AM, Sa-Sousa A, et al. Validation of control of allergic rhinitis and asthma test for children (CARATKids) – a prospective multicenter study. *Pediatr Allergy Immunol.* 2014;25:173–9.
 75. Associação Portuguesa de Medicina Geral e Familiar. 2as Jornadas do GRESP. 2014.
 76. Familiar A.P.d.M.G.e. 13º Encontro Nacional de Internos e Jovens Médicos de Família. 2014.
 77. Associação Portuguesa de Medicina Geral e Familiar. 15º Congresso Nacional de MGF e 9º ENIJMF. 2010.
 78. Associação Portuguesa de Medicina Geral e Familiar. 17º Congresso Nacional de MGF e 11º ENIJMF. 2012.
 79. Associação Portuguesa de Medicina Geral e Familiar. 18º Congresso Nacional de MGF e 12º ENIJMF. 2013.
 80. Associação Portuguesa de Medicina Geral e Familiar. 19º Congresso Nacional de MGF e 14º ENIJMF. 2015.
 81. Familiar APdMGe. 19th WONCA Europe Conference. 2014.
 82. Associação Portuguesa dos Médicos de Clínica Geral. 27º Encontro Nacional de Clínica Geral. 2010.
 83. Associação Portuguesa dos Médicos de Clínica Geral. 28º Encontro Nacional de Clínica Geral. 2011.
 84. Familiar APdMGe. 29º Encontro Nacional APMGF. 2012.
 85. Associação Portuguesa de Medicina Geral e Familiar. 30º Encontro Nacional APMGF. 2013.
 86. Associação Portuguesa de Medicina Geral e Familiar. 31º Encontro Nacional APMGF. 2014.
 87. Associação Portuguesa de Medicina Geral e Familiar. 32º Encontro Nacional APMGF. 2015.
- B. Malheiro^a, P.M. Teixeira^{b,*1}, L. Alves^{a,b,c}, J. Yaphe^{a,b}, J. Correia de Sousa^{a,b,d}
- ^a School of Medicine, University of Minho, Braga, Portugal
^b ICVS/3B's – PT Government Associate Laboratory, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Portugal
^c St. André de Canidelo Family Health Unit, Vila Nova de Gaia, Portugal
^d Horizonte Family Health Unit, Matosinhos, Porto, Portugal
- * Corresponding author.
 E-mail address: teixeira.pms@gmail.com (P.M. Teixeira).
¹ Shared first author.
- <https://doi.org/10.1016/j.pulmoe.2019.01.005>
 2531-0437/
 © 2019 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Factors associated with loss to follow-up in Tuberculosis treatment in the Huambo Province, Angola



Dear Editor,

Loss to follow-up during treatment is considered one of the obstacles in the fight against tuberculosis (TB).¹ Angola is among the top thirty countries in the world ranked by TB burden with a TB treatment coverage of 51% and a success rate of 27% for new cases and 28% for previously treated cases.²

The health network of Huambo province, in addition to hospitals, centres and health posts, includes a sanatorium hospital, eleven outpatient clinics and an Anti-Tuberculosis Dispensary (ATD) – responsible for the TB outpatient management.

With the aim of identifying the factors related to loss to follow-up in TB treatment in the population of Huambo we designed a prospective and retrospective study in patients followed in the ATD with a TB diagnosis between October 2015 and January 2016 ($n=353$).

The data collection was performed using a questionnaire developed for this study and filled out at monthly follow-up consultations by nursing technicians and researchers

in the TB field, after receiving specific training. Patients were individually questioned in a closed environment on the ATD premises to maintain privacy, after clarification of the study and informed consent. End-of-treatment results were obtained from the clinical records of the patients in the end of August 2016. Loss to follow-up was considered for patients who started treatment but did not complete it.³

All statistical analysis was performed using R version 3.3.2. A univariate and multivariate logistic regression was performed with the response being loss to follow-up in TB treatment. For the multivariate analysis the complete model was determined starting with a selection of variables whose p -value was <0.10 in the univariate analysis, and using the stepwise regression method that minimizes the AIC (Akaike Information Criterion). The model discrimination ability was given by the area under the ROC curve. The significance level was set at 0.05.

The study was authorized by the General Directorate of the Sanitary Hospital of Huambo, Angola and approved by the Ethics Committee of the São João Hospital Center and the Faculty of Medicine of the University of Porto, Portugal.

Of the 353 patients who started treatment, 309 were included in the analysis, with no age limitation, both genders, new cases as well pre-treated cases. The 44 patients excluded from the analysis consisted of 42 who did not have

Table 1 Sociodemographic and clinical characteristics associated with the loss to follow-up in TB treatment in the Huambo Province.

	Treatment Success	Lost to follow up	Univariate Analysis		Multivariate Analysis	
			OR (95% IC)	p-value	OR (95% IC)	p-value
Patients n	207	102				
<i>County</i>						
Huambo	175 (84.5)	77 (75.5)	1		1	
Outside of Huambo	32 (15.5)	25 (24.5)	1.78 (0.98, 3.19)	0.056	1.3 (0.99, 1.29)	0.075
<i>Sex</i>						
Male	130 (62.8)	73 (71.6)	1			
Female	77 (37.2)	29 (28.4)	0.67 (0.40, 1.11)	0.128		
<i>Educational qualifications</i>						
Illiterate	24 (11.6)	15 (14.7)	1			
Primary school	61 (29.5)	26 (25.5)	0.68 (0.31, 1.52)	0.343		
Secondary education (1C)	55 (26.6)	34 (33.3)	0.99 (0.46, 2.17)	0.978		
Secondary education (2C) or +	67 (32.4)	27 (26.5)	0.64 (0.29, 1.43)	0.273		
<i>Age</i>						
30 or + years	100 (48.3)	33 (32.4)	1		1	
- than 30 years	107 (51.7)	69 (67.6)	1.95 (1.20, 3.24)	0.008*	1.22 (1.09, 1.35)	0.000*
<i>Employment</i>						
Non regular occupation	172 (83.1)	83 (81.4)	1			
Regular occupation	35 (16.9)	19 (18.6)	1.12 (0.60, 2.07)	0.708		
<i>Consumption of alcoholic beverages</i>						
Non-drinker	123 (59.4)	54 (52.9)	1			
Current drinker	33 (15.9)	26 (25.5)	1.79 (0.98, 3.29)	0.058		
Ex-drinker	51 (24.6)	22 (21.6)	0.98 (0.54, 1.77)	0.954		
<i>Smoking tobacco</i>						
Non-smoker	173 (83.6)	73 (71.6)	1		1	
Current smoker	16 (7.7)	18 (17.6)	2.67 (1.29, 5.57)	0.008*	1.31 (1.11, 1.55)	0.002*
Ex smoker	18 (8.7)	11 (10.8)	1.45 (0.63, 3.18)	0.363	1.16 (0.97, 1.39)	0.113
<i>Serology</i>						
Positive	16 (7.7)	10 (9.8)	1			
Negative	191 (92.3)	92 (90.2)	0.77 (0.34, 1.82)	0.538		
<i>Family Support</i>						
Yes	161 (77.8)	66 (64.7)	1		1	
No	46 (22.2)	36 (35.3)	1.91 (1.13, 3.22)	0.015*	1.13 (1.01, 1.27)	0.041*

* $p < 0.05$.

a known result for the HIV test and 2 who were transferred to other units

Overall the patients included had a median age of 26 years old (IQR 21–37), 203 (65.7%) of whom were male, 255 (82.5%) had non-regular occupation, 177 (57.3%) did not consume alcoholic beverages, 246 (79.6%) did not smoke tobacco, 283 (91.6%) had negative HIV serology and 227 (73.5%) had family support during treatment (Table 1).

Among the included patients, being younger than 30 years old produced a 2.69-fold (95% CI 1.56–4.78, $p < 0.001$) increase in the risk of being lost to follow-up, smoking tobacco resulted in a 3.54-fold (95% CI 1.61–7.99, $p = 0.002$) higher risk. Not having family support and living outside Huambo city were both associated with an increased risk of loss to follow-up of 75% (95% CI 1.00–3.04, $p = 0.047$ and 95% CI 0.94–3.24, $p = 0.078$ respectively). The excluded patients differed from those included in the study as they had a higher proportion of people living outside Huambo city.

Our findings show that being younger than 30 was a risk factor for loss to follow-up. Besides that, our results do not differ much from studies conducted in South Africa⁴ and Morocco where being older than 24 and being older than 50,⁵ respectively, were considered protective factors for loss to follow-up. As for what life is like in Angola, we should take into account that the majority of the population is extremely young, since 65% are 24 years old or younger.⁶ One possible explanation for this is the socioeconomic situation in Angola which often means the family is responsible for many young patients and also leads to a lack of access to transportation. In the present study, it was observed that patients without family support had a higher risk of loss to follow-up, and this was also observed in studies conducted in South Africa.⁷ In Angola loss to follow-up exceeded 10%.² Based on our study, in order to increase adherence of TB patients to treatment, in addition to the DOTs some incentive measures should be adopted such as providing patient transportation and a basic food basket.

In this study there was a limitation that complete treatment cases were considered as successful even though these could not be classified as cured because there was no microbiological evidence at the end of treatment.

Based on the results, we conclude that age, lack of family support and smoking tobacco were associated with loss to follow-up in TB treatment in the Huambo province.

Further reading

1. Tachfouti N, Slama K, Berraho M, Elfakir S, Benjelloun MC, El Rhazi K, et al. Determinants of tuberculosis treatment default in Morocco: results from a national cohort study. *Pan Afr Med J.* 2013;14:121.
2. WHO. Global Tuberculosis Report 2018. Geneva: WHO/CDS/TB/2018.20 World Health Organization; 2018.
3. Organization WH. Guidance for national tuberculosis programmes on the management of tuberculosis in children. World Health Organization; 2014.
4. Kigozi G, Heunis C, Chikobvu P, Botha S, van Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa. *Int J Infect Dis.* 2017;54:95–102.
5. Cherkaoui I, Sabouni R, Ghali I, Kizub D, Billieux AC, Bennani K, et al. Treatment default amongst patients with tuberculosis in urban morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results. *PLOS ONE.* 2014;9:9.
6. Instituto Nacional de Estatística. Resultados Definitivos do recenseamento Geral da População e da Habitação de Angola 2014. Av. Ho Chi Minh, Luanda, Angola, 2016. p. 48.
7. Mabunda JT, Khoza LB, Van den Borne HB, Lebese RT. Needs assessment for adapting TB directly observed treatment intervention programme in Limpopo Province, South Africa: a community-based participatory research approach. *Afr J Primary Health Care Family Med.* 2016;8:e1–7.

E. Santos^{a,b,*}, Ó. Felgueiras^{c,d}, O. Oliveira^{a,e,f},
R. Duarte^{a,g,h}

^a *EpiUnit – Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas, n° 135, 4050-600 Porto, Portugal*

^b *Instituto Superior Politécnico da Universidade José Eduardo dos Santos, Huambo, Angola*

^c *Mathematics Department, Faculty of Sciences of the University of Porto, Porto, Portugal*

^d *Centre of Mathematics of the University of Porto, Porto, Portugal*

^e *Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal*

^f *ICVS/3B's, PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal*

^g *Departamento de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal*

^h *Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Universidade do Porto, Porto, Portugal*

* Corresponding author.

E-mail address: milalionjanga@yahoo.com.br (E. Santos).

<https://doi.org/10.1016/j.pulmoe.2019.03.003>
2531-0437/

© 2019 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).